预测免疫治疗反应的多种潜在生物标志物——大海捞针
The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.
作者信息
Adam Tamiem, Becker Therese M, Chua Wei, Bray Victoria, Roberts Tara L
机构信息
Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW 2170, Australia.
School of Medicine, Western Sydney University, Campbelltown, NSW 2170, Australia.
出版信息
Cancers (Basel). 2021 Jan 13;13(2):277. doi: 10.3390/cancers13020277.
Abstract
Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.
摘要
免疫检查点抑制剂（ICIs）正越来越多地应用于各种晚期恶性肿瘤。尽管在某些患者中取得了令人鼓舞的结果，但大多数患者不会从中获益，并且有发生潜在严重免疫相关不良事件（irAEs）的风险。因此，开发预测性生物标志物对于个性化治疗和改善治疗结果至关重要。许多生物标志物已显示出有前景的结果，包括来自肿瘤的（程序性细胞死亡配体1（PD-L1）、肿瘤突变负荷（TMB）、干扰素基因刺激物（STING）和含半胱天冬酶激活和招募结构域的凋亡相关斑点样蛋白（ASC））、来自血液的（外周血单核细胞（PBMCs）、循环肿瘤DNA（ctDNA）、外泌体、细胞因子和金属螯合剂），最后是微生物组。
相似文献
1
The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.预测免疫治疗反应的多种潜在生物标志物——大海捞针
Cancers (Basel). 2021 Jan 13;13(2):277. doi: 10.3390/cancers13020277.
2
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.循环肿瘤 DNA 肿瘤突变负荷（ctDNA TMB）在非小细胞肺癌中的临床意义。
Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.
3
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?非小细胞肺癌中的血浆生物标志物与免疫检查点抑制剂：用于更好地选择患者的新工具？
Cancers (Basel). 2019 Aug 29;11(9):1269. doi: 10.3390/cancers11091269.
4
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
5
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.针对肿瘤突变负担状态和程序性死亡配体 1 表达预测检查点抑制剂治疗结局的应用进行的目标文献回顾。
Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9.
6
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
7
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.转移性肾细胞癌免疫治疗反应的预测生物标志物
Front Oncol. 2020 Aug 12;10:1644. doi: 10.3389/fonc.2020.01644. eCollection 2020.
8
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?程序性细胞死亡配体-1（PD-L1）作为非小细胞肺癌（NSCLC）治疗的生物标志物——我们找错方向了吗？
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.
9
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.晚期非小细胞肺癌（NSCLC）免疫治疗反应和毒性的循环生物标志物：综述
Cancers (Basel). 2021 Apr 9;13(8):1794. doi: 10.3390/cancers13081794.
10
Possible Biomarkers for Cancer Immunotherapy.癌症免疫治疗的潜在生物标志物。
Cancers (Basel). 2019 Jul 3;11(7):935. doi: 10.3390/cancers11070935.
引用本文的文献
1
The ascendancy of eosinophil counts in non-small cell lung cancer: a potential marker for predicting response and survival under nivolumab treatment.非小细胞肺癌中嗜酸性粒细胞计数的优势：一种预测纳武单抗治疗反应和生存的潜在标志物。
Am J Cancer Res. 2024 Oct 25;14(10):5095-5104. doi: 10.62347/KRTH2276. eCollection 2024.
2
Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.肺免疫预后指数在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的预后价值：一项荟萃分析。
Pathol Oncol Res. 2024 Jun 20;30:1611773. doi: 10.3389/pore.2024.1611773. eCollection 2024.
3
Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status.小分子抑制剂在癌症免疫治疗及相关生物标志物中的应用现状。
Front Immunol. 2023 Oct 31;14:1297175. doi: 10.3389/fimmu.2023.1297175. eCollection 2023.
4
A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.肾癌的新治疗格局：人类微生物群与肾癌改善预后的关联
Cancers (Basel). 2023 Feb 1;15(3):935. doi: 10.3390/cancers15030935.
5
Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.西达本胺联合酪氨酸激酶抑制剂重塑肿瘤免疫微环境，并在免疫检查点抑制剂联合治疗对 PD-1 耐药 CT26 荷瘤小鼠中降低肿瘤进展。
Int J Mol Sci. 2022 Sep 14;23(18):10677. doi: 10.3390/ijms231810677.
6
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.肠道微生物群在转移性肾细胞癌免疫调节中的作用。
Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122714. doi: 10.1177/17588359221122714. eCollection 2022.
7
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.用于免疫相关不良反应早期预测的生物标志物和风险因素：综述。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2018894. doi: 10.1080/21645515.2021.2018894. Epub 2022 Feb 2.
8
Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward.为儿童急性髓系白血病免疫治疗铺平道路：当前认知与未来方向
Cancers (Basel). 2021 Aug 28;13(17):4364. doi: 10.3390/cancers13174364.
9
Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma.散发性和遗传性透明细胞肾细胞癌的分子和代谢亚型。
Genes (Basel). 2021 Mar 9;12(3):388. doi: 10.3390/genes12030388.
10
Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma.端粒结合因子 2 表达与髓系来源抑制细胞浸润与皮肤黑色素瘤患者临床结局的相关性。
Oncoimmunology. 2021 Mar 19;10(1):1901446. doi: 10.1080/2162402X.2021.1901446.
本文引用的文献
1
Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.热点还是冷门：肿瘤突变负荷 (TMB) 作为泌尿生殖系统癌症免疫治疗反应的生物标志物。
Urology. 2021 Jan;147:119-126. doi: 10.1016/j.urology.2020.10.030. Epub 2020 Nov 1.
2
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.辅助纳武利尤单抗对比伊匹单抗用于可切除 IIIB-C 期和 IV 期黑色素瘤（CheckMate 238 研究）：一项多中心、双盲、随机、对照、III 期临床试验的 4 年结果。
Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19.
3
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.阿维鲁单抗维持治疗晚期或转移性尿路上皮癌。
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
4
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.肿瘤内铜调节 PD-L1 表达并影响肿瘤免疫逃逸。
Cancer Res. 2020 Oct 1;80(19):4129-4144. doi: 10.1158/0008-5472.CAN-20-0471. Epub 2020 Aug 18.
5
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.美国食品药品监督管理局（FDA）批准帕博利珠单抗用于肿瘤突变负荷（TMB）≥10的成人和儿童患者：一项以赋予患者及其医生权力为核心的决定。
Ann Oncol. 2020 Sep;31(9):1115-1118. doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5.
6
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药治疗与安慰剂用于无疾病证据的 IV 期黑色素瘤患者（IMMUNED）：一项随机、双盲、安慰剂对照、II 期试验。
Lancet. 2020 May 16;395(10236):1558-1568. doi: 10.1016/S0140-6736(20)30417-7.
7
The importance of exosomal PDL1 in tumour immune evasion.外泌体 PD-L1 在肿瘤免疫逃逸中的重要性。
Nat Rev Immunol. 2020 Apr;20(4):209-215. doi: 10.1038/s41577-019-0264-y. Epub 2020 Jan 21.
8
STING activation in cancer immunotherapy.STING 激活在癌症免疫治疗中的作用。
Theranostics. 2019 Oct 15;9(25):7759-7771. doi: 10.7150/thno.37574. eCollection 2019.
9
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.如何区分接受免疫治疗的癌症患者的假性进展与真性进展。
Am J Cancer Res. 2019 Aug 1;9(8):1546-1553. eCollection 2019.
10
Functions of Exosomes in the Triangular Relationship between the Tumor, Inflammation, and Immunity in the Tumor Microenvironment.外泌体在肿瘤微环境中肿瘤、炎症和免疫的三角关系中的作用。
J Immunol Res. 2019 Aug 1;2019:4197829. doi: 10.1155/2019/4197829. eCollection 2019.
Zotero 插件